Loading clinical trials...
Loading clinical trials...
A Randomized Open-label Phase 2 Study of TALazoparib With or Without ENzaluTamide in Patients With Metastatic Castration-Resistant Prostate Cancer and HRR Mutations After Progression on Abiraterone Acetate
Conditions
Interventions
Talazoparib with enzalutamide
Talazoparib
Locations
2
United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
May 1, 2026
Primary Completion Date
March 1, 2029
Completion Date
March 1, 2030
Last Updated
April 24, 2026
NCT06190899
NCT07332000
NCT05283330
NCT07103018
NCT07451795
NCT06616597
Lead Sponsor
Prostate Cancer Clinical Trials Consortium
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions